EUVIMEDEUVIMED entdecken
Crossref

Personalized survival models for choosing irradiated tumor burden on combined radiotherapy and immune checkpoint inhibitors in stage IV NSCLC patients

Yeseul Kim, Joongyo Lee, Ibrahim Chamseddine, Clemens Grassberger, Hong In Yoon, Kyung Hwan Kim, Yeona Cho, Wonmo Sung

Physica Medica · 2026

DOI: 10.1016/j.ejmp.2026.105751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physica Medica, 2026. Verfasst von Yeseul Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, the Republic of Korea; Department of Medical Scie…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, Tumor Burden. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Yonsei University College of Medicine, Ministry of Science and ICT, South Korea, Catholic Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To assess the effects of irradiated tumor burden (ITB) and key prognostic factors for patients with advanced non-small cell lung cancer (NSCLC) who received a combination treatment of radiotherapy (RT) and immune checkpoint inhibitors (ICI). METHODS: We retrospectively reviewed 79 patients with stage 4 NSCLC treated with ICI after RT. The linear and non-linear prediction models were trained to predict individual risk-based on the optimal parameter set selected from 14 clinical features including patient, tumor, treatment, and immunologic factors. We introduced a new prognostic factor, ITB, as the volume fraction of tumor that irradiated to investigate the impact of radiotherapy for the combination treatment. ITB's correlation with clinical variables was examined using log-rank survival tests and Pearson correlation maps. RESULTS: Overall survival (OS) prediction indicates the non-linear random survival forest (RSF) model surpassed both the Cox linear model and gradient boosting model (RSF c-index = 0.78 90 %CI [0.77-0.80], Cox c-index = 0.75 90 %CI [0.74-0.76], GBM c-index = 0.77 90 %CI [0.76-0.78]; t-test P < 0.001 between RSF and Cox). Major prognostic factors for the final OS models are ITB, metastasis extent, and RT-induced lymphopenia. Patients with an ITB over 50 % exhibited improved outcomes (Median OS: 15.8 vs 7.9 months, p < 0.001; median progression-free survival (PFS): 12.5 vs 7.4 months, p < 0.001). ITB demonstrated independent predictive power, as no linear correlation with other variables was evident. CONCLUSION: Our findings endorse RT followed by ICI as a favorable protocol for advanced NSCLC, advocating for ITB's integration into future RT-ICI trial designs due to its significant prognostic implication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsTumor BurdenPrecision MedicineHumansFemaleMaleNeoplasm StagingRetrospective StudiesMiddle AgedAgedSurvival AnalysisPrognosisAged, 80 and over

Stichwörter der Autor:innen

Advanced non-small cell lung cancerClinical prognostic factorImmune-checkpoint inhibitorsOutcome predictionRandom survival forestSurvival model

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, the Republic of Korea; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, the…
  • Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, the Republic of Korea; Department of Radiation Oncology, Gil Medical Center, Gachon University College of Medic…
  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, United States; Department of Radiation Oncology, University of Washington, Seattle, United States.
  • Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, the Republic of Korea.
  • Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, the Republic of Korea. Electronic address: iamyona@yuhs.ac.

Förderung

  • Yonsei University College of Medicine
  • Ministry of Science and ICT, South Korea
  • Catholic Medical Center
  • National Research Foundation of Korea

Zitieren

APA

Kim, Y., Lee, J., Chamseddine, I., Grassberger, C., Yoon, H. I., Kim, K. H., Cho, Y., & Sung, W. (2026). Personalized survival models for choosing irradiated tumor burden on combined radiotherapy and immune checkpoint inhibitors in stage IV NSCLC patients. Physica Medica. https://doi.org/10.1016/j.ejmp.2026.105751

Vancouver

Kim Y, Lee J, Chamseddine I, Grassberger C, Yoon HI, Kim KH, et al. Personalized survival models for choosing irradiated tumor burden on combined radiotherapy and immune checkpoint inhibitors in stage IV NSCLC patients. Physica Medica. 2026. doi:10.1016/j.ejmp.2026.105751

BibTeX
@article{Kim2026,
  author = {Kim, Yeseul and Lee, Joongyo and Chamseddine, Ibrahim and Grassberger, Clemens and Yoon, Hong In and Kim, Kyung Hwan and Cho, Yeona and Sung, Wonmo},
  title = {Personalized survival models for choosing irradiated tumor burden on combined radiotherapy and immune checkpoint inhibitors in stage IV NSCLC patients},
  journal = {Physica Medica},
  year = {2026},
  doi = {10.1016/j.ejmp.2026.105751}
}
Kostenlos starten →